DoW Alzheimer’s Transforming Diagnosis Award

Key Facts

Status: Forecasted

Posted date: May 1, 2026

Archive date: October 24, 2026

Close date: September 24, 2026

Opportunity ID: 362179

Opportunity number: HT942526AZRPTRDA

Opportunity category: Discretionary

Agency name: Dept. of the Army -- USAMRAA

Agency code: DOD-AMRAA

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Grant
Category of Funding Activity
  • Science and Technology and other Research and Development
Eligible Applicants
  • Unrestricted
Tools
Categories (use these for quoted searches)
  • agency_code:dod_amraa
  • category_of_funding_activity:science_and_technology_and_other_research_and_development
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:unrestricted
  • funding_instrument_type:grant
  • opportunity_category:discretionary
  • status:forecasted
Description

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis.Distinctive Features:Clinical research is allowed, however clinical trials and animal research are prohibited. Preliminary data are required.Community collaboration is required for studies prospectively enrolling human subjects.Study Population: The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.Career Initiation or Transition (CIT) Partnership Option: The TrDA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission.

DoW Alzheimer’s Transforming Diagnosis Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis.Distinctive Features:Clinical research is allowed, however clinical trials and animal research are prohibited. Preliminary data are required.Community collaboration is required for studies prospectively enrolling human subjects.Study Population: The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.Career Initiation or Transition (CIT) Partnership Option: The TrDA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission.
[Forecasted] DoW Alzheimer’s Transforming Diagnosis Award
Forecasted
Dept. of the Army -- USAMRAA
Science and Technology and other Research and Development
Grant
Unrestricted
2026-05-01